"PSTI's ability to vary the cell phenotype for a specific therapy is unique in the regenerative medicine space." (3/6/14) Pluristem Therapeutics Inc. - The Life Sciences Report Interview with George Zavoico Moreá>
"The fact that CGIX was able to get a practiced sales force to take its products to market is a very big deal." (3/5/14) Cancer Genetics Inc. - The Life Sciences Report Interview with Ben Haynor Moreá>
"NEO is in the process of launching next-generation sequencing for the clinical trial market; the deal with Covance sets the stage for the company to go to the next level." (2/27/14) NeoGenomics Laboratories - The Life Sciences Report Interview with Debjit Chattopadhyay Moreá>
Some companies with expected catalysts
Johnson & Johnson Merck & Co. Neuralstem Inc.
Top Investors and Analysts Use this Exclusive Report to Anticipate the Prospects of Medical and Biotech Stocks.
Now you can, too!
Access to the BioMed Tracker Quarterly Outlook Reports usually costs $2,000. For a limited time you can get access to the Report for FREE.
Biomedical stocks can soar depending on key catalysts and outcomes, such as FDA approval, regulatory changes, and clinical studies. The more accurately you can anticipate the results, the higher your profits.
We know that portfolio managers and analysts will pay big bucks for top-flight investment research. And for many investors and analysts the ultimate interactive biotech & pharmaceutical investment tool is the BioMedTracker Report from Sagient Research:
- The BioMedTracker Outlook report is sorted by catalyst type, date and company, giving you quick, sortable access to exclusive information.
- The Report usually costs $2,000 per year.
Right now, for a limited time, Sagient is offering free access to the current BioMedTracker Report to readers of Streetwise Reports.